Nausea and vomiting of pregnancy (NVP) affects up to 90% of pregnancies. Diclectin (doxylamine/pyridoxine) is the only anti-emetic approved in Canada for NVP, at a maximum dose of 4 tablets/day. However, some women receive higher doses, up to 12 tablets/day. In this study we compared the neurocognitive development of children from four mother-child groups: (1) NVP and >4 tablets Diclectin, (2) NVP and ≤ 4 tablets Diclectin, (3) NVP and no treatment and (4) no NVP. Children received a full age-appropriate psychological assessment. All groups scored in the normal range for IQ and cognition tests. The Diclectin-exposed groups scored significantly higher on a small number of subtests, but none of the differences could be considered clinically significant. No dose-dependent effects were observed. Above manufacturer recommended doses of Diclectin do not appear to harm neurodevelopment and should be considered safe for the treatment of NVP.
| Identifer | oai:union.ndltd.org:TORONTO/oai:tspace.library.utoronto.ca:1807/33349 |
| Date | 21 November 2012 |
| Creators | Carey, Nathalie |
| Contributors | Gideon, Koren |
| Source Sets | University of Toronto |
| Language | en_ca |
| Detected Language | English |
| Type | Thesis |
Page generated in 0.002 seconds